Результаты поиска

Терапия на хепарин-индуцирана тромбоцитопения

Лечението на хепарин-индуцираната тромбоцитопения (ХИТ) е от решаващо значение за намаляване на риска от тромбоемболични усложнения и смъртност. Основен принцип на терапията е незабавното прекратяване на хепариновата експозиция, последвано от започване на алтернативен нехепаринов антикоагулант в терапевтична доза. Сред най-често използваните нехепаринови антикоагуланти са аргатробан, бивалирудин, данапароид, фондапаринукс и директни перорални антикоагуланти (ДОАК). Изборът на конкретно средство зависи от редица фактори, включително бъбречна и чернодробна функция, индивидуален риск от кървене,

Совпадение в полном тексте источника
… Fondaparinux in acute heparin-induced thrombocytopenia: a case series. J Thromb Haemost. 2011;9(12):2501- 3. 16. Warkentin TE, Pai M, Sheppard JI, et al. … Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin- release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9(12):2389-96. 17. Warkentin TE, Davidson BL, Buller HR, et al. …

Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO).

Patients with cancer, both hematologic and solid malignancies, are at increased risk for thrombosis and thromboembolism. In addition to general risk factors such as immobility and major surgery, shared by non-cancer patients, cancer patients are exposed to specific thrombotic risk factors. These include, among other factors, cancer-induced hypercoagulation, and chemotherapy-mediated endothelial dysfunction as well as tumor-cell-derived microparticles. After an episode of thrombosis in a cancer patient, secondary thromboprophylaxis to prevent recurrent thromboembolism has long been established

Совпадение в полном тексте источника
… Several clinical trials have confirmed the efficacy of low-dose UFH, LMWH, and fondaparinux (FPX) in preventing DVT and PE in patients undergoing major surgery, without significantly increasing bleeding complications. … Thromboprophylaxis should be performed with LMWH, UFH (second choice), or fondaparinux. The exact peri-operative timing of these drugs is described in the respective Summary of Product Characteristics (SmPC). …

Pharmacovigilance in oncology.

Background Side effects of cancer therapy are one of the most important issues faced by cancer patients during their illness. Pharmacovigilance, namely the science and activities aimed at monitoring the safety of drugs, is particularly important in oncology, due to the intrinsic biologic toxicity of antineoplastic agents, their narrow therapeutic windows, and the high doses and rigid timing of treatment regimens. Aim of the review To identify the main issues in carrying out an effective pharmacovigilance activity in oncology. Method We searched PubMed for articles about pharmacovigilance in re

Совпадение в полном тексте источника
… , warfarin Anticoagulant therapy, low molecular weight heparin, fondaparinux. … , warfarin | Anticoagulant therapy, low molecular weight heparin, fondaparinux. …

Anticoagulation challenges in cancer patients: prevention, detection, and treatment strategies.

Cancer-associated thrombosis is one of the most common and serious complications in oncology patients, contributing significantly to morbidity and mortality. This prothrombotic state is driven by cancer-related factors, systemic inflammation, and treatment-induced endothelial injury. Anticoagulation management in these patients is challenging, as both thrombotic and bleeding risks must be carefully balanced, particularly in those with cardiovascular comorbidities. This review examines the complexities of anticoagulation in cancer-associated thrombosis through three clinical cases. Case 1 focus

Совпадение в полном тексте источника
… Surgical cancer patients, particularly those undergoing major surgery, benefit from perioperative thromboprophylaxis using LMWH or fondaparinux. … Hospitalized Cancer Patients | Thromboprophylaxis recommended if VTE risk outweighs bleeding risk (preferred agents: LMWH, fondaparinux). Surgical Cancer Patients (Perioperative) | Perioperative thromboprophylaxis recommended (preferred agents: LMWH, fondaparinux). …

Guidelines on deep vein thrombosis of the Brazilian Society of Angiology and Vascular Surgery.

Deep vein thrombosis is one of the main causes of inpatient and outpatient morbidity, both in medical and surgical patients, significantly impacting mortality statistics and requiring prompt diagnosis so that treatment can be initiated immediately. This document was prepared and reviewed by 11 specialists certified by the Brazilian Society of Angiology and Vascular Surgery, who searched the main databases for the best evidence on the diagnostic (physical examination, imaging) and therapeutic approaches (heparin, coumarins, direct oral anticoagulants, fibrinolytics) to the disease.

Совпадение в полном тексте источника
… We recommend, with a high level of evidence, initial treatment with subcutaneous (SC) LMWH, intravenous (IV) or monitored SC UFH, fixed-dose SC UFH, or SC fondaparinux, followed by long-term oral anticoagulation. … LMWH vs fondaparinux Fondaparinux is noninferior to LMWH in terms of VTE recurrence, major bleeding, or death. VKAs VKAs should be initiated on the first treatment day, combined with UFH, LMWH, or fondaparinux, except in patients who have contraindications to their use. …

Post hip fracture orthogeriatric care-a Canadian position paper addressing challenges in care and strategies to meet quality indicators.

INTRODUCTION: Osteoporosis is a major disease state associated with significant morbidity, mortality, and health care costs. Less than half of the individuals sustaining a low energy hip fracture are diagnosed and treated for the underlying osteoporosis. OBJECTIVE: A multidisciplinary Canadian hip fracture working group has developed practical recommendations to meet Canadian quality indicators in post hip fracture care. METHODS: A comprehensive narrative review was conducted to identify and synthesize key articles on post hip fracture orthogeriatric care for each of the individual sections

Совпадение в полном тексте источника
… The National Institute for Health and Care Excellence (NICE) recommends the use of LMWH or fondaparinux for 28 to 35 days, while Thrombosis Canada similarly supports enoxaparin, dalteparin, tinzaparin, or fondaparinux for 14 to 35 days post-operatively [ 96 , 97 ]. … Trauma Association (OTA) Low dose aspirin (81 mg BID); low molecular weight heparin; fondaparinux 28–35 days 2019 American Society of Hematology Low molecular weight heparin; unfractionated heparin Not specified 2019 Thrombosis Canada Enoxaparin; dalteparin; tinzaparin; fondaparinux 14–35 days 2018 European …

Cancer-Associated Thrombosis: Pathophysiology, Laboratory Assessment, and Current Guidelines.

Dysregulated hemostasis in cancer patients is associated with various clinical conditions, from thromboembolic complications to disseminated intravascular coagulation. Despite the well-established association between cancer and thromboembolic complications, the mechanisms involved are not completely elucidated. There are several predisposing factors in cancer for increased thrombus generation, such as immobilization and chemotherapy. The term cancer-associated thrombosis (CAT) has been introduced to describe the close bidirectional relationship between cancer and thromboembolic events. Convent

Совпадение в полном тексте источника
… ESMO [ 93 ] | Recommended agents: UFH, LMWH, apixaban, rivaroxaban, fondaparinux for initial acute phase treatment. - LMWH is recommended over UFH and fondaparinux. - UFH is a considerable option for patients with renal dysfunction (CrCl < 30 mL/min). | Vitamin-K antagonists are not recommended. … Lastly, no significant differences in terms of bleeding, mortality, or thromboembolic outcomes have been reported between different heparin agents (LMWH, UFH, and fondaparinux) [ 100 ]. 9. …

Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study.

BACKGROUND: Multiple myeloma (MM) is associated with a high risk of thrombosis, particularly during the first months of treatment including immunomodulatory drugs (IMiDs). There is no consensus on prevention of thromboembolic risk in patients with de novo MM, and identification of patients requiring anticoagulant thromboprophylaxis remains challenging. Evaluating coagulability by an in vitro thrombin generation (TG) test might be a way of identifying such patients. OBJECTIVE: To determine whether TG assessment could reveal an increase in coagulability during the first three chemotherapy cycle

Совпадение в полном тексте источника
… The treatment choice and the use of antithrombotic prophylaxis with aspirin, heparin or fondaparinux was left to the discretion of the treating physician. Sample collection All blood samples were analyzed in a core laboratory at the U1059 INSERM unit (University of Saint‐Etienne, France). … For patients on heparin or fondaparinux, no injection was performed within at least 24 hours before blood sampling. In the case of heparin prophylaxis, anti‐Xa activities were checked. …

Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines.

BACKGROUND: Interventional pain management involves diagnosis and treatment of chronic pain. This specialty utilizes minimally invasive proc … , apixaban (Eliquis®), rivaroxaban (Xarelto®), edoxaban (Savaysa®, Lixiana®), Betrixaban(Bevyxxa®), fondaparinux (Arixtra®) prior to interventional techniques with individual consideration of pharmacokinetics and pharmacodynamics of the drugs and individual risk factors increases safety.5. There is good evidence that diagnosis of epidural hematoma is based on …

Iliocaval and iliofemoral venous stenting for obstruction secondary to tumor compression.

BackgroundCancer patients with pelviabdominal masses can suffer from lower extremity symptoms due to venous compression. The effectiveness of venous stenting has been established in extrinsic venous compression in benign conditions like May-Thurner syndrome. In this retrospective study we evaluate the efficacy and safety of caval, iliocaval and iliofemoral venous stenting for cases of extrinsic venous compression caused by malignant masses in cancer patients.MethodsIRB-approved retrospective review of patients who underwent iliofemoral venography with venoplasty and stenting between January 20

Совпадение в полном тексте источника
… median (IQR: interquartile range) or n(%) a Other cancers included Breast, Chondrosarcoma, Hepatocellular, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Penile SCC, Sarcoma, PEComa b Other symptoms included itching, redness, cramping, venous ulcers, varicosities c Other anticoagulants included Fondaparinux … median (IQR: interquartile range) or n(%) a Other cancers included Breast, Chondrosarcoma, Hepatocellular, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Penile SCC, Sarcoma, PEComa b Other symptoms included itching, redness, cramping, venous ulcers, varicosities c Other anticoagulants included Fondaparinux …

Hematology

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Complex does not bind thrombin due to short length DVT prophylaxis Acute DVT/PE Acute coronary syndrome HITT (no cross reactivity with heparin-dependent anti-platelet antibodies) For DVT prophylaxis, fondaparinux 2.5 mg SC daily (start 6–8 h after surgical hemostasis) For acute clots, fondaparinux 5 … Complex does not bind thrombin due to short length | DVT prophylaxis Acute DVT/PE Acute coronary syndrome HITT (no cross reactivity with heparin-dependent anti-platelet antibodies) | For DVT prophylaxis, fondaparinux 2.5 mg SC daily (start 6–8 h after surgical hemostasis) For acute clots, fondaparinux …

Anticoagulant management of cancer-associated thrombosis and thrombocytopenia: a retrospective chart review.

BACKGROUND: Patients with cancer-associated thrombosis (CAT) are at an increased risk of recurrent thrombosis and bleeding, especially if there is treatment- or disease-related thrombocytopenia. While direct oral anticoagulants (DOACs) are used in the management of CAT, low molecular weight heparin (LMWH) continues to be recommended for CAT with thrombocytopenia. OBJECTIVES: This study aimed to identify the rates of recurrent venous thromboembolism (VTE) and bleeding in patients with CAT and thrombocytopenia treated with DOACs compared with LMWH. METHODS: A retrospective review of patients w

Совпадение в полном тексте источника
… As such, the number of occurrences is not equivalent to the total number of thrombocytopenic patients per time interval. b Two thrombocytopenic patients were receiving fondaparinux during days 8-14 and are represented by the “Other” category. … As such, the number of occurrences is not equivalent to the total number of thrombocytopenic patients per time interval. b Two thrombocytopenic patients were receiving fondaparinux during days 8-14 and are represented by the “Other” category. …

Treating Infected Non-Healing Venous Leg Ulcers with Medical-Grade Honey: A Prospective Case Series.

Venous leg ulcers (VLUs) are hard-to-heal wounds and are prone to microbial colonization. Innovative and improved therapies are thus required to resolve local infection and enhance the wound healing process. The objective of this study was to evaluate the effectiveness of medical-grade honey (MGH) for the treatment of clinically infected and non-healing VLUs. This prospective case series included nine patients with an average age of 83.4 years (range: 75-91 years) with a total of eleven VLUs, previously ineffectively treated with various products. Major risk factors for the appearance of VLUs

Совпадение в полном тексте источника
… The patient presented limited mobility and received anticoagulant (apixaban 2.5 mg, fondaparinux sodium 2.5 mg/0.5 mL) and glucocorticoid therapy (prednisolone 5 mg). … Medical history included CVI, AHT, peripheral artery disease (PAD), hyperthyroidism, hyperlipidemia, arthritis, and osteoporosis, while receiving anticoagulant (fondaparinux sodium 2.5 mg/0.5 mL) and glucocorticoid (methylprednisolone 4 mg) therapy. …

The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study.

Background Cancer is a well-known risk factor of preventable thromboembolic disease. This study aims to provide guidance on the prevention and management of cancer-associated thrombosis (CT) that tailors prophylactic and therapeutic options for medical and surgical oncology patients presenting to health care settings in Saudi Arabia. Methods The present consensus was developed in concordance with the modified Delphi-based approach, which incorporates a face-to-face meeting between two voting rounds to gain experts' feedback on the proposed statements. All experts were either oncologists, hemat

Совпадение в полном тексте источника
… Even though apixaban appears to have a RR of bleeding as dalteparin, recommendations have been cautious about suggesting it in patients with GI and GU malignancies until further data are obtained. 94 Apixaban, rivaroxaban, LMWH, UFH, or fondaparinux may be used as initial anticoagulants. … DOACs, LMWH, UFH, or fondaparinux, can be used as initial anticoagulants. Among parenteral agents, LMWH is preferred over UFH in the absence of severe renal impairment | 100% 3. LMWH is preferred for patients with acute VTE at high risk for bleeding or with GI malignancy | 83.3% 4. …

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel.

The introduction of new therapeutic agents for multiple myeloma (MM), including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has improved the outcomes of patients but, in parallel, has changed the frequency and epidemiology of thrombotic events. Thrombosis is now a significant cause of morbidity and mortality in MM patients, and optimal thromboprophylaxis is far from being reached. Moving from the recognition that the above issue represents an unmet clinical need, an expert panel assessed the scientific literature and composed a framework of recommendations for imp

Совпадение в полном тексте источника
… For those with an IMPEDE score of ≥4 points or a SAVED score of ≥2 points, the recommendation is enoxaparin (40 mg/day subcutaneously), warfarin (target International Normalized Ratio, 2.0–3.0), fondaparinux (2.5 mg/day sub-cutaneously), or a DOAC, such as rivaroxaban at a dose of 10 mg/day orally or … Dose adjustments of low molecular weight heparin and fondaparinux in renal insufficiency. …

Palliative Chemotherapy: Does It Only Provide False Hope? The Role of Palliative Care in a Young Patient With Newly Diagnosed Metastatic Adenocarcinoma.

Case Study A 48-year-old female with recent diagnosis of adenocarcinoma of unknown origin and metastatic disease to the peritoneum initially … turned positive, consistent with heparin-induced thrombocytopenia. Enoxaparin was discontinued, and fondaparinux (Arixtra) was initiated. Platelet count recovered shortly thereafter. The patient required intense symptom management due to intractable abdominal pain and nausea and vomiting despite adequate venting G-tube decompression. Medical management was max …

Pharmacoeconomic evaluation of direct oral anticoagulants for cancer-associated thrombosis: a systematic review.

OBJECTIVE: To synthesize pharmacoeconomic evidence of prevention and treatment of venous thromboembolism (VTE) in cancer patients with direct oral anticoagulants (DOACs) and evaluate the quality of the studies. METHODS: PubMed, Embase, Scopus, the Cochrane Library, the Center for Reviews and Dissemination Database, the Health Technology Assessment Database, and the China National Knowledge Infrastructure Database were searched to collect economic evaluations. The search covered publications from their inception until June 13, 2024. Study selection was conducted independently by two researcher

Совпадение в полном тексте источника
… Society of Clinical Oncology ( 11 ), the European Society for Medical Oncology ( 12 ), and the American National Comprehensive Cancer Network ( 13 , 14 ), the recommended pharmacological treatments or prevention include warfarin, unfractionated heparin (UFH), low molecular weight heparins (LMWHs), fondaparinux … Currently, the mainstream recommended anticoagulants for the prevention and treatment of CAT include warfarin, parenteral anticoagulants (UFH, LMWHs, or fondaparinux), and DOACs. …

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients-A Review.

Venous thromboembolism (VTE) is an important aspect in cancer patients. There are various pharmacological methods used for thrombotic event treatment. DOACs (direct-acting oral anticoagulants) are gaining popularity among both physicians and researchers and are slowly starting to replace VKAs (vitamin K antagonists), thus becoming a substitute or alternative option for LMWHs (low-molecular-weight heparins). In this article, we present DOACs' main therapeutic advantages and disadvantages in patients with cancer. The only major concern with using DOACs is the higher risk of bleeding; however, th

Совпадение в полном тексте источника
… The parenteral group includes unfractionated heparins (UFHs), low-molecular-weight heparins (LMWHs), fondaparinux, and bivalirudin, whereas oral agents are vitamin K antagonists (VKAs) and non-vitamin K antagonist direct oral anticoagulants (DOACs). … Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin Thromb. Res. 2015 136 1273 1279 10.1016/j.thromres.2015.08.009 26489727 122. Muñoz Martín A.J. Gallardo Díaz E. García Escobar I. Macías Montero R. Martínez-Marín V. …

Venous thromboembolism in China: epidemiology, management strategies, and future directions.

Venous thromboembolism (VTE) is one of the leading causes of unexpected death among hospitalized patients. It is also a preventable condition, and its incidence can be substantially reduced through active and effective prophylaxis. In recent years, the burden of VTE in China has continued to increase, driven by population aging, a rising prevalence of malignancy, a growing volume of complex surgery, and advances in imaging and laboratory testing. At present, the clinical management paradigm for VTE in China has gradually evolved from the traditional acute event-centered 'diagnosis-treatment' p

Совпадение в полном тексте источника
… Common parenteral agents include UFH, LMWH, and fondaparinux. In daily practice, LMWH is often preferred for hemodynamically stable patients. It is convenient to use and has predictable pharmacokinetics. … Fondaparinux sodium and low molecular weight heparin for venous thromboembolism prophylaxis in Chinese patients with major orthopedic surgery or trauma: a real-world study BMC Surg 22 2022 243 10.1186/s12893-022-01652-6 35751113 PMC9229095 79 Huang J. Shao Q. …

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review.

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, represents a major cause of morbidity and mortality in patients with cancer. Arterial thromboembolism, including myocardial infarction and stroke, is also prevalent. Risk differs in subgroups, with higher rates observed in specific cancers including pancreas, stomach, and multiple myeloma. Thromboprophylaxis is recommended for most patients with active cancer hospitalized for medical illnesses and after major cancer surgery. Outpatient thromboprophylaxis is not routinely recommended, but emerging data suggest

Совпадение в полном тексте источника
… In addition, evidence from the literature shows that the current prophylactic doses (enoxaparin 40 mg, dalteparin 5,000 IU, fondaparinux 2.5 mg), may not reduce the overall rate of VTE compared with placebo and may be suboptimal for high-risk populations ( 67 ). … In summary, for the choice and the duration of treatment, current ASCO guidelines suggest the following: Initial anticoagulation may include LMWH (preferred over UFH if renal function is normal), fondaparinux, or rivaroxaban. …